Who are Tenofovir + lamivudine + raltegravir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ELV/COBI/FTC/TAF, DTG/3TC/ABC + ELV/COBI/FTC/TAF, Switch to DTG + 3TC, bictegravir/emtricitabine/tenofovir alafenamide, dolutegravir/abacavir/lamivudine, Long-acting Cabotegravir injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenofovir-lamivudine-raltegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tenofovir + lamivudine + raltegravir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenofovir + lamivudine + raltegravir (Tenofovir + lamivudine + raltegravir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI + INSTI. Area: Infectious Diseases.

phase 3 NRTI + INSTI HIV integrase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Tenofovir + lamivudine + raltegravir (Tenofovir + lamivudine + raltegravir) — ANRS, Emerging Infectious Diseases. Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tenofovir + lamivudine + raltegravir TARGET	Tenofovir + lamivudine + raltegravir	ANRS, Emerging Infectious Diseases	phase 3	NRTI + INSTI	HIV integrase
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Switch to DTG + 3TC	Switch to DTG + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
Long-acting Cabotegravir injection	Long-acting Cabotegravir injection	MU-JHU CARE	marketed	Integrase strand transfer inhibitor (INSTI)	HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI + INSTI class)

ANRS, Emerging Infectious Diseases · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenofovir + lamivudine + raltegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/tenofovir-lamivudine-raltegravir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab